28373747|t|Andrographolide Activates Keap1 / Nrf2 / ARE / HO-1 Pathway in HT22 Cells and Suppresses Microglial Activation by Aβ42 through Nrf2 -Related Inflammatory Response
28373747|a|Therapeutic approach of Alzheimer's disease (AD) has been gradually diversified. We examined the therapeutic and preventive potential of andrographolide, which is a lactone diterpenoid from Andrographis paniculata, and focused on the Kelch-like ECH-associated protein 1 (Keap1)/ nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-mediated heme oxygenase (HO)-1 - inducing effects and the inhibitory activity of amyloid beta (Aβ)42 - induced microglial activation related to Nrf2 and nuclear factor κB (NF-κB)-mediated inflammatory responses. Andrographolide induced the expression and translocation of Nrf2 from the cytoplasm to the nucleus, thereby activating antioxidant response element (ARE) gene transcription and HO-1 expression in murine hippocampal HT22 cells. Andrographolide eliminated intracellular Aβ42 in BV-2 cells and decreased the production of interleukin (IL)-6, IL-1β, prostaglandin (PG)E2, and nitric oxide (NO) because of artificial phagocytic Aβ42. It decreased pNF-κB accumulation in the nucleus and the expression of inducible nitric oxide synthase (i-NOS) and cyclooxygenase II (COX-II) in the microglial BV-2 cell line. In summary, andrographolide activates Nrf2 -mediated HO-1 expression and inhibits Aβ42 - overexpressed microglial BV-2 cell activation. These results suggested that andrographolide might have the potential for further examination of the therapeutics of AD.
28373747	0	15	Andrographolide	T121	C0051821
28373747	16	25	Activates	T052	C1879547
28373747	26	31	Keap1	T116,T123	C1449230
28373747	34	38	Nrf2	T116,T123	C1565076
28373747	41	44	ARE	T114,T123	C3494205
28373747	47	51	HO-1	T116,T126	C1565862
28373747	63	73	HT22 Cells	UnknownType	C0814990
28373747	78	88	Suppresses	T045	C0038855
28373747	89	110	Microglial Activation	T043	C1326169
28373747	114	118	Aβ42	T116,T123	C0169424
28373747	127	131	Nrf2	T116,T123	C1565076
28373747	141	162	Inflammatory Response	T046	C1155266
28373747	163	183	Therapeutic approach	T169	C0039798
28373747	187	206	Alzheimer's disease	T047	C0002395
28373747	208	210	AD	T047	C0002395
28373747	260	271	therapeutic	T169	C0039798
28373747	276	286	preventive	T169	C0445202
28373747	287	296	potential	T080	C3245505
28373747	300	315	andrographolide	T121	C0051821
28373747	328	347	lactone diterpenoid	T109	C0304008
28373747	353	376	Andrographis paniculata	T002	C1256659
28373747	397	432	Kelch-like ECH-associated protein 1	T116,T123	C1449230
28373747	434	439	Keap1	T116,T123	C1449230
28373747	442	485	nuclear factor (erythroid-derived 2)-like 2	T116,T123	C1565076
28373747	487	491	Nrf2	T116,T123	C1565076
28373747	502	516	heme oxygenase	T116,T126	C1565862
28373747	517	523	(HO)-1	T116,T126	C1565862
28373747	526	534	inducing	T169	C0205263
28373747	535	542	effects	T080	C1280500
28373747	551	570	inhibitory activity	T052	C3463820
28373747	574	593	amyloid beta (Aβ)42	T116,T123	C0169424
28373747	596	603	induced	T169	C0205263
28373747	604	625	microglial activation	T043	C1326169
28373747	637	641	Nrf2	T116,T123	C1565076
28373747	646	663	nuclear factor κB	T116,T129	C0079904
28373747	665	670	NF-κB	T116,T129	C0079904
28373747	681	703	inflammatory responses	T046	C1155266
28373747	705	720	Andrographolide	T121	C0051821
28373747	721	728	induced	T169	C0205263
28373747	733	743	expression	T045	C1171362
28373747	748	761	translocation	T043	C0599893
28373747	765	769	Nrf2	T116,T123	C1565076
28373747	779	788	cytoplasm	T026	C0010834
28373747	796	803	nucleus	T026	C0007610
28373747	824	852	antioxidant response element	T114,T123	C3494205
28373747	854	857	ARE	T114,T123	C3494205
28373747	859	877	gene transcription	T045	C0040649
28373747	882	886	HO-1	T116,T126	C1565862
28373747	887	897	expression	T045	C1171362
28373747	901	907	murine	T015	C0026809
28373747	908	919	hippocampal	T023	C0019564
28373747	920	930	HT22 cells	UnknownType	C0814990
28373747	932	947	Andrographolide	T121	C0051821
28373747	959	972	intracellular	T082	C0178719
28373747	973	977	Aβ42	T116,T123	C0169424
28373747	981	991	BV-2 cells	T025	C0206116
28373747	996	1005	decreased	T081	C0205216
28373747	1010	1042	production of interleukin (IL)-6	T040	C1819459
28373747	1044	1049	IL-1β	T040	C1819435
28373747	1051	1064	prostaglandin	T039	C1514503
28373747	1065	1071	(PG)E2	T039	C1514503
28373747	1077	1089	nitric oxide	T044	C1157570
28373747	1091	1093	NO	T044	C1157570
28373747	1106	1116	artificial	T080	C2004457
28373747	1117	1127	phagocytic	T025	C0031307
28373747	1128	1132	Aβ42	T116,T123	C0169424
28373747	1137	1146	decreased	T081	C0205216
28373747	1147	1153	pNF-κB	T116,T129	C0079904
28373747	1154	1166	accumulation	T033	C4055506
28373747	1174	1181	nucleus	T026	C0007610
28373747	1190	1200	expression	T045	C1171362
28373747	1204	1213	inducible	T169	C0205263
28373747	1214	1235	nitric oxide synthase	T116,T126	C0132555
28373747	1237	1242	i-NOS	T116,T126	C0132555
28373747	1248	1265	cyclooxygenase II	T116,T126	C0387583
28373747	1267	1273	COX-II	T116,T126	C0387583
28373747	1282	1307	microglial BV-2 cell line	T025	C0206116
28373747	1321	1336	andrographolide	T121	C0051821
28373747	1337	1346	activates	T052	C1879547
28373747	1347	1351	Nrf2	T116,T123	C1565076
28373747	1362	1366	HO-1	T116,T126	C1565862
28373747	1367	1377	expression	T045	C1171362
28373747	1382	1390	inhibits	T052	C3463820
28373747	1391	1395	Aβ42	T116,T123	C0169424
28373747	1398	1411	overexpressed	T045	C1514559
28373747	1412	1443	microglial BV-2 cell activation	T043	C1326169
28373747	1451	1458	results	T033	C0683954
28373747	1474	1489	andrographolide	T121	C0051821
28373747	1505	1514	potential	T080	C3245505
28373747	1546	1558	therapeutics	T169	C0039798
28373747	1562	1564	AD	T047	C0002395